$0.33+0.00 (+0.62%)
ALPS Group Inc (ALPS) is a Medical/Nursing Services company listed on NASDAQ. In the last 30 days Quantisnow tracked 4 wire items for ALPS, including 3 SEC filings and 1 press release or news item. The most recent was published Oct 30, 2026.
News · 26 weeks14+200%
2026-05-102026-11-01
Mix790d
- SEC Filings4(57%)
- Other2(29%)
- Earnings1(14%)
Latest news
25 items- SECSEC Form 6-K filed by ALPS Group Inc6-K - Alps Group Inc (0002025774) (Filer)
- PRAlps Group Inc Announces Shareholder Approval for a Share Consolidation, Share Capital Increase, and Adoption of Second Amended and Restated Memorandum and Articles of AssociationKUALA LUMPUR, Malaysia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc ("Alps" or "the Company") (NASDAQ:ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that its shareholders approved, in accordance with Cayman Islands law, all of the proposals submitted at the Company’s Extraordinary General Meeting held on October 30, 2026 (the "EGM"). At the EGM, the Alps shareholders approved (i) a share consolidation of the Company’s ordinary shares and its preferred shares at a ratio of one-for-five, whereby every five shares consolidated into one (the "Share Consolidation"); (ii) an increase in the Company’s authorized share capital (the "Share Capital Incre
- SECSEC Form 6-K filed by ALPS Group Inc6-K - Alps Group Inc (0002025774) (Filer)
- SECSEC Form 6-K filed by ALPS Group Inc6-K - Alps Group Inc (0002025774) (Filer)
- SECSEC Form 6-K filed by ALPS Group Inc6-K - Alps Group Inc (0002025774) (Filer)
- PRAlps Group Inc Reports Fiscal Year 2026 Financial Results and Provides Business UpdateRevenue Grew 44% to $4.9 Million, Led by Continued Growth Across Cellular Therapy, Medical Testing, Laboratory and Aesthetics Beauty Services, and Healthcare Products Began Trading on the Nasdaq Global Market Under the Ticker Symbol "ALPS" in October 2025, Marking the Company's Transition to the U.S. Public Markets KUALA LUMPUR, Malaysia, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc ("Alps" or "the Company") (NASDAQ:ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced its financial results for the year ended March 31, 2026, and provides a business update. The Company has filed its annual report on Form 20-F, including its audited financial statements
- SECSEC Form 20-F filed by ALPS Group Inc20-F - Alps Group Inc (0002025774) (Filer)
- SECSEC Form NT 20-F filed by ALPS Group IncNT 20-F - Alps Group Inc (0002025774) (Filer)
- SECSEC Form 6-K filed by ALPS Group Inc6-K - Alps Group Inc (0002025774) (Filer)
- PRAlps Group Inc Launches Patient-Derived Organoid Program to Advance Personalized Cancer Care in Southeast AsiaKUALA LUMPUR, Malaysia, June 23, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc ("Alps" or "the Company") (NASDAQ:ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced its expansion into patient-derived organoid (PDO) technology through a Research and Collaboration Agreement with Dr. Kong Wai Mun, Executive Director of Axiocell Biotech and a biomedical scientist with more than 17 years of experience in translational research and preclinical model development. Under the agreement, Alps is launching an internal PDO program targeting personalized cancer treatment and preclinical drug screening, a fast-growing field in precision oncology. According to Future Market I
- SECSEC Form 6-K filed by ALPS Group Inc6-K - Alps Group Inc (0002025774) (Filer)
- PRAlps Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022KUALA LUMPUR, Malaysia, June 09, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc ("Alps" or "the Company") (NASDAQ:ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that its subsidiary, MyGenome Sdn. Bhd. ("MyGenome"), has received accreditation for its Whole Genome Sequencing ("WGS") under MS ISO 15189:2022. MS ISO 15189:2022 is an internationally recognized clinical standard that sets rigorous requirements for quality and competence in medical laboratories. Unlike targeted genetic panels, WGS examines a patient's complete DNA sequence, making accreditation at this level a meaningful technical distinction. The expanded accreditation confirms that MyGenome's g
- SECSEC Form 6-K filed by ALPS Group Inc6-K - Alps Group Inc (0002025774) (Filer)
- PRAlps Group Inc Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyKUALA LUMPUR, Malaysia, May 19, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the "Company" or "Alps Group"), the parent company of Alps Life Sciences Inc. ("Alps Holdco"), a fully integrated biotechnology research and healthcare platform specializing in predictive, preventive, and precision medicine, today announced that on May 15, 2026, the Company received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that based on the closing bid price of the ordinary shares of the Company for the last 30 consecutive business days, the Company is currently not in compliance with the continued listing requirement of Nasdaq under Nasdaq Lis
- INSIDERSEC Form 3 filed by new insider Lee Hee Hang3 - Alps Group Inc (0002025774) (Issuer)
- SECSEC Form 6-K filed by ALPS Group Inc6-K - Alps Group Inc (0002025774) (Filer)
- PRAlps Group Appoints Former Ernst & Young Partner to Board of Directors, Strengthening Governance and Capital Markets OversightKUALA LUMPUR, Malaysia, April 17, 2026 (GLOBE NEWSWIRE) -- Alps Group Inc (the "Company" or "Alps Group"), the parent company of Alps Life Sciences Inc. ("Alps Holdco"), a biotechnology research and healthcare platform focused on predictive, preventive, and precision medicine, announced the appointment of Mr. Hee H. Lee ("Mr. Lee") to its Board of Directors (the "Board"), effective April 17, 2026. The Company's Board will increase from five (5) to six (6) directors in connection with this appointment. Mr. Lee is considered independent under applicable Nasdaq rules and is expected to serve as a member of the Audit Committee and the Compensation Committee. Mr. Lee has over 35 years of exper
- INSIDERSEC Form 3 filed by new insider Poh Chit Laa3 - Alps Group Inc (0002025774) (Issuer)
- INSIDERSEC Form 3 filed by new insider Chua Boon Ping3 - Alps Group Inc (0002025774) (Issuer)
- INSIDERSEC Form 3 filed by new insider Chew Yoke Ling3 - Alps Group Inc (0002025774) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cheing Lye-Ping3 - Alps Group Inc (0002025774) (Issuer)
- INSIDERSEC Form 3 filed by new insider Mohamed Suleiman Bin3 - Alps Group Inc (0002025774) (Issuer)
- INSIDERSEC Form 3 filed by new insider Manickam Ravichandran3 - Alps Group Inc (0002025774) (Issuer)
- INSIDERSEC Form 3 filed by new insider Low Wei Sim3 - Alps Group Inc (0002025774) (Issuer)
- INSIDERSEC Form 3 filed by new insider Tham Seng Kong3 - Alps Group Inc (0002025774) (Issuer)
ALPS FAQ
5 questionsWhat is the latest news on ALPS?
In the last 30 days Quantisnow tracked 4 wire items for ALPS: 3 SEC filings and 1 press release or news item. The most recent was published on October 30, 2026.Where does ALPS stock trade?
ALPS Group Inc (ALPS) is listed on NASDAQ.What sector and industry is ALPS in?
ALPS Group Inc operates in the Health Care sector, Medical/Nursing Services industry.What companies are similar to ALPS?
Notable peers in the same industry include BTSG (BrightSpring Health Services Inc.), CHE (Chemed Corp), HIMS (Hims & Hers Health Inc.), LFST (LifeStance Health Group Inc.), OPCH (Option Care Health Inc.). Compare ALPS side-by-side with any of them on Quantisnow.How can I track ALPS on Quantisnow?
Quantisnow aggregates ALPS Group Inc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ALPS to receive live email and push alerts on every new disclosure.